908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith Sells 10,236 Shares

908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith sold 10,236 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.34, for a total value of $23,952.24. Following the transaction, the chief financial officer now directly owns 109,870 shares in the company, valued at $257,095.80. This represents a 8.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

908 Devices Trading Up 3.5 %

Shares of NASDAQ:MASS opened at $2.37 on Wednesday. 908 Devices Inc. has a twelve month low of $1.81 and a twelve month high of $7.91. The company’s 50 day moving average is $2.35 and its 200 day moving average is $3.27.

Institutional Trading of 908 Devices

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in 908 Devices in the third quarter valued at $36,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of 908 Devices in the 3rd quarter valued at about $45,000. Townsquare Capital LLC purchased a new stake in shares of 908 Devices in the third quarter worth about $50,000. Drive Wealth Management LLC acquired a new stake in 908 Devices during the third quarter worth about $50,000. Finally, Concurrent Investment Advisors LLC purchased a new position in 908 Devices during the fourth quarter valued at approximately $52,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of 908 Devices in a research note on Saturday. Leerink Partners reissued a “market perform” rating and set a $4.00 target price (down previously from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Stifel Nicolaus decreased their price target on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Leerink Partnrs lowered shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Finally, Stephens reissued an “overweight” rating and issued a $6.00 target price on shares of 908 Devices in a research report on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.